Skip to content
OpenCapital
Get started

Pfizer PFE Liabilities, Noncurrent, Fair Value Disclosure

Other financials

Income statement

See full
Revenue$14.5B+5.4%
Gross profit$10.9B+0.3%
Net income$2.7B-9.4%
EPS (diluted)$0.47-9.6%

Balance sheet

See full
Cash & equivalents$1.8B+18.8%
Total debt$64.4B+5.0%
Total equity$90.1B-0.3%
Total assets$207.62B-0.2%

Cash flow

See full
Operating cash flow$2.6B+12.0%
CapEx$436.0M-22.7%
Free cash flow$2.2B+23.0%

Valuation

See full
Market cap$143.68B+11.1%
Enterprise value$206.35B+9.2%
P/E11.9×—
P/S2.3×+0.2×

Profitability

See full
Gross margin73.5%+1.2pp
Net margin15.7%—

Returns & leverage

See full
Return on equity10.6%—
Debt / equity0.7×0.0×
Current ratio1.2×0.0×

Where this comes from

Reported directly by Pfizer in its filing.

Tagged under the XBRL concept pfe:LiabilitiesNoncurrentFairValueDisclosure.

The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pfizer's liabilities, noncurrent, fair value disclosure.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pfizer's liabilities, noncurrent, fair value disclosure?
Pfizer (PFE) reported liabilities, noncurrent, fair value disclosure of $3.03B in Q1 2026.